384

medialink_digital...

GlaxoSmithKline [NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FluLavalTM [Influenza Virus Vaccine] for the active immunization of adults 18 years and older against influenza disease, commonly known as the flu, caused by influenza virus types A and B contained in the vaccine. The approval of FluLaval is another major step towards increasing the influenza vaccine supply in the United States, following the introduction of GSK’s Fluarix® [Influenza Virus Vac...

fda, influenza, flu vaccine, glaxosmithkline, flulaval, medicine,